Chest
Circulating Antigen KL-6 and Lactate Dehydrogenase for Monitoring Irradiated Patients with Lung Cancer
Section snippets
Subjects
Fifteen patients with lung cancer who received radiation therapy with line accelerator were selected for this study. Six patients contracted radiation pneumonitis (pneumonitis group, Table 1) and the other nine patients did not (control group, Table 2). All patients with pneumonitis had cough and a continuous fever. Five of them showed infiltrative changes which emerged just on the irradiated area on their chest x-ray films. The remaining patient showed infiltrative shadows all over the lung
Time Course of Irradiated Patients
Followed-up levels of serum KL-6, LDH activity, and CRP are shown in Figure 1 for the pneumonitis group, and in Figure 2 for the control group.
In the pneumonitis group, all of the serum KL-6, LDH activity, and CRP developed the tendency to increase their levels before and after the diagnosis of radiation pneumonitis.
In the control group, on the other hand, serum KL-6 did not show one-sided change of the levels. Two patients, indicated by closed circles in Figure 2, showed increased KL-6 levels
DISCUSSION
Serum KL-6 appeared to be a sensitive marker for serologic diagnosis of radiation pneumonitis, and the change of its level was quite different from that of serum CRP. In all of the six patients of the pneumonitis group, serum levels of KL-6 were significantly increased from 1.7 to 63-fold according to the complication of radiation pneumonitis. In two of them, the increase was observed even before the diagnosis of pneumonitis. Though the increase of serum KL-6 level was also observed in four of
REFERENCES (33)
- et al.
Age factor relevant to the development of radiation pneumonitis in radiotherapy of lung cancer
Int J Rad Oncol Biol Phys
(1988) - et al.
Steroids for pneumonitis after bone-marrow transplantation
Lancet
(1987) - et al.
Serum lactate dehydrogenase levels in adults and children with acquired immune deficiency syndrome (AIDS) and AIDS-related complex: possible indicator of B cell lymphoproliferation and disease activity: effect of intravenous gammaglobulin on enzyme levels
Am J Med
(1985) - et al.
Elevated serum procollagen III aminopeptide levels in sarcoidosis
Chest
(1990) X-ray diagnosis of radiation injuries of the lung
Dis Chest
(1960)- et al.
Complications of radiation therapy: the thorax
Sem Roentgenol
(1974) - et al.
New serum indicator of interstitital pneumonitis activity: sialylated carbohydrate antigen KL-6
Chest
(1989) - et al.
Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma
Jpn J Clin Oncol
(1988) - et al.
Radiation reaction in the lung after continuous and split-course megavoltage radiotherapy of bronchial carcinoma
Br J Radiol
(1967) - et al.
Some factors altering the severity of acute radiation pneumonitis: variation with cortisone, heparin, and antibiotics
Radiology
(1960)
Pulmonary effects of radiation therapy
Ann Intern Med
Bone marrow transplantation and the lung
Thorax
Widespread pulmonary fibrosis as a major clinical manifestation of chronic graft-versus-host disease
Bone Marrow Transplant
Use of bronchoalveolar lavage cytology and determination of protein contents in pulmonary complications of bone marrow transplant recipients
Bone Marrow Transplant
Gallium-67 scintigraphy in lung diseases
Thorax
Cited by (89)
Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis
2017, Respiratory InvestigationCitation Excerpt :In recent years, serum markers, such as KL-6, SP-D, and SP-A have shown some utility for assessing disease severity in different interstitial lung diseases, including IPF. Data on the prognostic value of these biomarkers in IPF are limited [1–7]. While some studies have reported that serum markers increase during acute exacerbation of IPF [6–8], others have reported that serum KL-6 levels at initial examination could serve as prognostic factors as the condition progresses [10,11]; no study has assessed the relationship between serial changes in serum KL-6 and disease progression or outcome in IPF.
Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases
2012, Respiratory InvestigationCitation Excerpt :The utility of KL-6/MUC1 in distinguishing RP from lung cancer is limited. However, the serum levels of KL-6/MUC1 are useful for the early diagnosis of RP in patients with lung cancer who receive radiation therapy [38,39]. Goto et al. monitored KL-6/MUC1 serum levels in patients with lung cancer at multiple time points after the start of radiation therapy and showed a correlation between the changes in serum KL-6/MUC1 levels and the clinical course of RP [82].
Serum KL-6 in fibrotic NSIP: Correlations with physiologic and radiologic parameters
2010, Respiratory MedicineCitation Excerpt :KL-6 was strongly expressed by atypical and/or regenerating type II pneumocytes in tissue sections from patients with interstitial lung diseases.4 Serum levels of KL-6 have been reported to be elevated in various interstitial lung diseases such as idiopathic pulmonary fibrosis, collagen vascular disease associated interstitial pneumonias, and other interstitial lung disorders.5–9 Several reports have reported the role of KL-6 in patients with idiopathic interstitial pneumonias (IIPs),10,11 Little study has, however, evaluated the value of serum KL-6 exclusively in patients with f-NSIP, distinct from other subtypes of IIPs.
Hypoxia enhances MUC1 expression in a lung adenocarcinoma cell line
2009, Biochemical and Biophysical Research Communications
The Radiation Effects Research Foundation is a private nonprofit foundation, supported equally by the Government of Japan with funding from the Ministry of Health and Welfare and the Government of the United States with funding from the Department of Energy through the National Academy of Sciences.
This study was supported in part by grant-in-aid for Scientific Research (No. 02807081) from the Ministry of Education, Science and Culture, Japan.
Manuscript received July 22; revision accepted October 22.